In:
European Journal of Haematology, Wiley, Vol. 103, No. 5 ( 2019-11), p. 460-471
Abstract:
R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the standard therapy for patients with previously untreated diffuse large B‐cell lymphomas (DLBCL). Dose‐dense two‐weekly ‘R‐CHOP‐14’ was not superior over three‐weekly ‘R‐CHOP‐21’ in randomised clinical trials (RCTs). We present real‐world data on effectiveness of R‐CHOP‐14 and R‐CHOP‐21 in patients with DLBCL treated in German routine practice. Methods We identified 582 patients with DLBCL treated with R‐CHOP‐14 or R‐CHOP‐21 in 92 sites from the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms. Patients’ schedules were classified by (a) length of the initial first cycle and (b) length of cycles 1‐4. Results About 55% of patients received R‐CHOP‐21, 45% R‐CHOP‐14, in median 6 cycles. 51% and 55% of patients, respectively, were able to continue their initial R‐CHOP‐14 and R‐CHOP‐21 schedule. While most characteristics between the patient cohorts were similar, patients receiving R‐CHOP‐21 presented slightly more often with tumour stage I and lower IPI risk. 3‐year overall survival of patients with R‐CHOP‐14 and R‐CHOP‐21 did not differ: 84% vs 84% (first cycle), 87% vs 89% (cycles 1‐4). Conclusions Patients with DLBCL in Germany are slightly more likely to receive R‐CHOP‐21 than R‐CHOP‐14. Both schedules are similarly effective in routine practice confirming the results from RCTs.
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
2027114-1